Cocrystal Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 25, 2025. Cocrystal Pharma, Inc. (COCP) is a Delaware corporation listed on The Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals. Proposals 1, 2, and 3 were approved. Proposal 4 was rendered moot due to the approval of the other proposals.
- Proposal 1 (Election of Directors): Six nominees were elected for a one-year term. All received majority support, though significant broker non-votes (2,136,203) were recorded for each nominee.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Equity Incentive Plan): Stockholders approved the 2025 Equity Incentive Plan.
- Proposal 4 (Adjournment): Moot.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard voting procedures.
Key Facts for Investor Verification
- Verify the specific terms and share reserve of the newly approved 2025 Equity Incentive Plan in the definitive proxy statement filed on May 5, 2025.
- Confirm the composition of the Board of Directors following the election of the six new members.
- Note the high volume of broker non-votes (approx. 2.1 million) on the director election, which may indicate significant shares held in street name without voting instructions.
- Review the upcoming fiscal year-end audit engagement with Weinberg & Company.